1. Academic Validation
  2. Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes

Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes

  • Proteome Sci. 2017 Jun 24:15:13. doi: 10.1186/s12953-017-0122-4.
André Mateus 1 Tomi A Määttä 1 Mikhail M Savitski 1
Affiliations

Affiliation

  • 1 European Molecular Biology Laboratory, Genome Biology Unit, Meyerhofstr. 1, 69117 Heidelberg, Germany.
Abstract

In recent years, phenotypic-based screens have become increasingly popular in drug discovery. A major challenge of this approach is that it does not provide information about the mechanism of action of the hits. This has led to the development of multiple strategies for target deconvolution. Thermal proteome profiling (TPP) allows for an unbiased search of drug targets and can be applied in living cells without requiring compound labeling. TPP is based on the principle that proteins become more resistant to heat-induced unfolding when complexed with a ligand, e.g., the hit compound from a phenotypic screen. The melting proteome is also sensitive to Other intracellular events, such as levels of metabolites, post-translational modifications and protein-protein interactions. In this review, we describe the principles of this approach, review the method and its developments, and discuss its current and future applications. While proteomics has generally focused on measuring relative protein concentrations, TPP provides a novel approach to gather complementary information on protein stability not present in expression datasets. Therefore, this strategy has great potential not only for drug discovery, but also for answering fundamental biological questions.

Keywords

Drug discovery; Mass spectrometry-based proteomics; Protein thermal stability; Tandem mass tags; Target deconvolution; Thermal proteome profiling.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12400
    99.75%, pan-Kinase Inhibitor
    Akt